The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
- 주제(키워드) Africa , biosimilars , cross-national study , drug utilisation , Europe , health policy , insulin glargine , prices
- 주제(기타) Public, Environmental & Occupational Health
- 설명문(일반) [Godman, Brian; Kurdi, Amanj] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Dept Pharmacoepidemiol, Glasgow, Lanark, Scotland; [Godman, Brian; Kurdi, Amanj] Sefako Makgatho Hlth Sci Univ, Sch Pharm, Div Publ Hlth Pharm & Management, Pretoria, South Africa; [Godman, Brian] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town, Malaysia; [Haque, Mainul] Natl Def Univ Malaysia, Fac Med & Def Hlth, Unit Pharmacol, Kuala Lumpur, Malaysia; [Leong, Trudy] South African Natl Dept Hlth, Essential Drugs Programme, Pretoria, South Africa; [Allocati, Eleonora; Banzi, Rita] Ist Ric Farmacol Mario Negri IRCCS, Ctr Hlth Regulatory Policies, Milan, Italy; [Kumar, Santosh] Karnavati Univ, Dept Periodontol & Implantol, Gandhinagar, India; [Islam, Salequl; Nahar, Shamsun] Jahangirnagar Univ, Dept Microbiol, Dhaka, Bangladesh; [Charan, Jaykaran; Dutta, Siddhartha; Abhayanand, Jha Pallavi; Kaur, Rimple Jeet] All India Inst Med Sci, Dept Pharmacol, Jodhpur, Rajasthan, India; [Akter, Farhana] Chittagong Med Coll, Dept Endocrinol, Chittagong, Bangladesh; [Kurdi, Amanj] Hawler Med Univ, Dept Pharmacol, Coll Pharm, Erbil, Iraq; [Vassalo, Carlos] Univ Nacl Litoral, Fac Ciencias Med, Santa Fe, Santa Fe, Argentina; [Abu Bakar, Muhammed] Chattogram Maa O Shishu Hosp, Dept Endocrinol & Metab, Med Coll, Chattogram, Bangladesh; [Rahim, Sagir Abdur] Endocrine & Metab Disorders Gen Hosp, Bangladesh Inst Res & Rehabil Diabet, Dhaka, Bangladesh; [Sultana, Nusrat] Bangabandhu Sheik Mujib Med Univ Hosp, Dept Endocrinol & Metab, Dhaka, Bangladesh; [Deeba, Farzana] Bangabandhu Sheik Mujib Med Univ, Dept Obstet & Gynaecol, Dhaka, Bangladesh; [Khan, M. A. Halim; Alam, A. B. M. Muksudul] Shaheed Suhrawardy Med Coll Hosp, Dhaka, Bangladesh; [Jahan, Iffat] Eastern Med Coll, Dept Physiol, Cumilla, Bangladesh; [Kamal, Zubair Mahmood] Natl Inst Mental Hlth NIMH, Dhaka, Bangladesh; [Hasin, Humaira] Epsom & St Helier Univ Hosp NHS Trust, Surrey, England; [Munzur-E-Murshid] Handicap Int, Womens Integrated Sexual Hlth WISH 2 Access Choic, Kurigram, Bangladesh; [Haque, Monami] Sq Toiletries Ltd, Human Resource Dept, Rupayan Ctr, Dhaka, Bangladesh; [Rwegerera, Godfrey Mutashambara] Sir Ketumile Masire Teaching Hosp, Dept Med, Gaborone, Botswana; [Rwegerera, Godfrey Mutashambara] Univ Botswana, Fac Med, Gaborone, Botswana; [do Nascimento, Renata Cristina Rezende Macedo] Univ Fed Ouro Preto, Sch Pharm, Dept Pharm, Postgrad Program Pharmaceut Sci CiPharma, Ouro Preto, Brazil; [Dias Godoi, Isabella Piassi] Univ Fed Sul & Sudeste Para, Inst Hlth & Biol Studies, Cidade Univ, Maraba, Brazil; [Dias Godoi, Isabella Piassi] Univ Fed Sul & Sudeste Para, Grp CNPq Epidemiol Econ & Pharmacol Studies Arbov, Maraba, Brazil; [Irfan, Mohammed] Univ Fed Pelotas, Fac Odontol, Pelotas, RS, Brazil; [Matowa, Patrick] Eswatini Med Christian Univ, Pharm Dept, Mbabane, Eswatini; [Acolatse, Joseph; Incoom, Robert] Cape Coast Teaching Hosp CCTH, Cape Coast, Ghana; [Sefah, Israel Abebrese] Keta Municipal Hosp, Ghana Hlth Serv, Pharm Dept, Keta Dzelukope, Ghana; [Sefah, Israel Abebrese] Univ Hlth & Allied Sci, Sch Pharm, Pharm Practise Dept Pharm Practise, Ho, Volta Region, Ghana; [Acharya, Jitendra] SP Med Coll, Dept Dent, Bikaner, India; [Opanga, Sylvia; Kimonge, David] Univ Nairobi, Sch Pharm, Dept Pharmaceut & Pharm Practise, Nairobi, Kenya; [Njeri, Lisper Wangeci] Kenyatta Natl Hosp, Dept Pharm, Nairobi, Kenya; [Kwon, Hye-Young] Mokwon Univ, Div Biol & Publ Hlth, Daejeon, South Korea; [Bae, SeungJin] Ewha Womans Univ, Coll Pharm, Seoul, South Korea; [Khuan, Karen Koh Pek] Friends Pharm Pekan Sg Besi 42G, Kuala Lumpur, Malaysia; [Abubakar, Abdullahi Rabiu] Bayero Univ, Fac Pharmaceut Sci, Dept Pharmacol & Therapeut, Kano, Nigeria; [Sani, Ibrahim Haruna] Yusuf Maitama Sule Univ YUMSUK, Coll Hlth Sci, Unit Pharmacol, Kano, Nigeria; [Khan, Tanveer Ahmed; Hussain, Shahzad] Natl Inst Hlth, Islamabad, Pakistan; [Saleem, Zikria] Univ Lahore, Dept Pharm Practise, Fac Pharm, Lahore, Pakistan; [Malande, Oliver Ombeva] Egerton Univ, Dept Child Hlth & Paediat, Nakuru, Kenya; [Malande, Oliver Ombeva] East Africa Ctr Vaccines & Immunisat ECAVI, Kampala, Uganda; [Piloya-Were, Thereza] Makerere Univ, Sch Med, Coll Hlth Sci, Kampala, Uganda; [Inotai, Andras] Natl Resources Fund FNR, Montevideo, Uruguay; [Alutuli, Luke] Univ Teaching Hosp Grp, Dept Pharm, Lusaka, Zambia; [Kalungia, Aubrey Chichonyi] Univ Zambia, Sch Hlth Sci, Dept Pharm, Lusaka, Zambia; [Hoxha, Iris] Univ Med, Dept Pharm, Fac Med, Tirana, Albania; [Markovic-Pekovic, Vanda] Univ Banja Luka, Dept Social Pharm, Fac Med, Banja Luka, Bosnia & Herceg; [Tubic, Biljana] Agcy Med Prod & Med Devices Bosnia & Herzegovina, Banja Luka, Bosnia & Herceg; [Tubic, Biljana] Univ Banja Luka, Dept Med Chem, Fac Med, Banja Luka, Bosnia & Herceg; [Petrova, Guenka; Tachkov, Konstantin] Med Univ Sofia, Dept Social Pharm & Pharmacoecon, Fac Pharm, Sofia, Bulgaria; [Laius, Ott] State Agcy Med, Tartu, Estonia; [Harsanyi, Andras] Eotvos Lorand Univ, Dept Hlth Policy & Hlth Econ, Budapest, Hungary; [Inotai, Andras] Syreon Res Inst, Budapest, Hungary; [Inotai, Andras] Semmelweis Univ, Ctr Hlth Technol Assessment, Budapest, Hungary; [Jakupi, Arianit] UBT Higher Educ Inst, Fac Pharm, Pristina, Kosovo; [Garuoliene, Kristina] Vilnius Univ, Inst Biomed Sci, Dept Pharm, Fac Med, Vilnius, Lithuania; [Gulbinovic, Jolanta] Vilnius Univ, Inst Biomed Sci, Dept Pathol Forens Med & Pharmacol, Fac Med, Vilnius, Lithuania; [Wladysiuk, Magdalene] Jagiellonian Univ, Med Coll, Chair Epidemiol & Prevent Med, Krakow, Poland; [Wladysiuk, Magdalene; Rutkowski, Jakub] HTA Consulting, Krakow, Poland; [Mardare, Ileana] Carol Davila Univ Med & Pharm Bucharest, Publ Hlth & Management Dept, Fac Med, Bucharest, Romania; [Furst, Jurij] Hlth Insurance Inst, Ljubljana, Slovenia; [McTaggart, Stuart] Publ Hlth Scotland, Edinburgh, Midlothian, Scotland; [MacBride-Stewart, Sean] Greater Glasgow & Clyde NHS GGC, Pharm Serv, Glasgow, Lanark, Scotland; [Pontes, Caridad; Zara, Corinne] Catalan Hlth Serv, Drug Dept, Barcelona, Spain; [Pontes, Caridad] Univ Autonoma Barcelona, Dept Pharmacol Therapeut & Toxicol, Barcelona, Spain; [Tagoe, Eunice Twumwaa] Univ Strathclyde, Business Sch, Dept Management Sci, Glasgow, Lanark, Scotland; [Jakovljevic, Mihajlo] Univ Kragujevac, Dept Global Hlth Econ & Policy, Kragujevac, Serbia; [Jakovljevic, Mihajlo] Hosei Univ Tokyo, Inst Comparat Econ Studies, Fac Econ, Tokyo, Japan
- 등재 SCIE, SSCI, SCOPUS
- 발행기관 FRONTIERS MEDIA SA
- 발행년도 2021
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000182245
- 본문언어 영어
- Published As http://dx.doi.org/10.3389/fpubh.2021.671961
초록/요약
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers. Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders. Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries. Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production. Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.
more